ClinicalTrials.gg
RecruitingNCT04068597Updated Jun 24, 2026

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

A Phase 1/2 interventional study of CCS1477 and Pomalidomide in Haematological Malignancy, Acute Myeloid Leukemia and Non Hodgkin Lymphoma, sponsored by CellCentric Ltd.. Recruiting at 39 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-24.

Sponsored by CellCentric Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2019; still recruiting 7 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
250
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 70 studies in Hematologic Neoplasms with a site in United Kingdom — 22 open to participants now, 28 under way, 11 of them phase 3. Hematologic Neoplasms · United Kingdom.

Planned enrollment
16th of 61
250 · median 77
Started
2019
with 2 others
Phase 1/2
13 of 70
2 open now
Primary completion
2027-03
later than 5 of 27 live
Registered
38th of 70
by date

Among the 70 studies in Hematologic Neoplasms with a site in United Kingdom, this one is the 16th largest by planned enrollment of the 61 interventional ones that give a count, is one of 3 that started in 2019, is one of 13 in phase 1/2, reaches primary completion later than 5 of the 27 other live ones, and was the 38th registered.

Hematologic Neoplasms

1,445 studies on the registry are indexed under Hematologic Neoplasms; 420 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

22 of the 70 studies in Hematologic Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:

16 more — sign in →

All 22 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 208 (66%) set no upper age limit and 78 (25%) stop at 75 or younger; 80 take children under 18; 34 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies in Hematologic Neoplasms with a site in United Kingdom, or all of them as a file.
02

Study summary

A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.

Read the detailed description

This includes patients with Peripheral T-cell lymphoma.

03

Conditions studied

  • Haematological Malignancy
  • Acute Myeloid Leukemia
  • Non Hodgkin Lymphoma
  • Multiple Myeloma
  • Higher-risk Myelodysplastic Syndrome
  • Peripheral T Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of consent
  • performance status 0-2
  • Patients with confirmed (per standard disease specific diagnostic criteria), haematological (NHL, MM and AML)
  • Must have previously received standard therapy
  • Adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Intervention with any chemotherapy, agents or other anti-cancer drugs within 14 days or 5 half-lives of the first dose
  • Major surgical procedure or significant traumatic injury within 4 weeks of the first dose of study treatment
  • Strong inhibitors of or CYP3A4 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment
  • Strong inducers of CYP3A4 within 4 weeks of the first dose of study treatment
  • Patients should discontinue statins prior to starting study treatment
  • CYP2C8 substrates with a narrow therapeutic range taken within 2 weeks of the first dose of study treatment
  • Any unresolved reversible toxicities from prior therapy > grade 1 at the time of starting study treatment (except alopecia and grade 2 neuropathy)
  • Any evidence of severe or uncontrolled systemic diseases
  • Any known uncontrolled inter-current illness
  • prolongation (> 470 msec)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Experimental
    CCS1477 dose escalation NHL/MM

    CCS1477 monotherapy

    Drug: CCS1477

  • Experimental
    CCS1477 dose escalation AML/Higher risk MDS

    CCS1477 monotherapy

    Drug: CCS1477

  • Experimental
    CCS1477 monotherapy expansion and combination dose finding and expansion NHL

    CCS1477 monotherapy, CCS1477 combination with lenalidomide

    Drug: CCS1477 · Drug: Lenalidomide

  • Experimental
    CCS1477 monotherapy expansion and combination dose finding and expansion - MM

    CCS1477 monotherapy, CCS1477 combination with pomalidomide-dexamethasone, CCS1477 combination with bortezomib-dexamethasone, CCS1477 combination with ixazomib-dexamethasone, CCS1477 combination with elranatamab, CCS1477 combination with teclistamab, CCS1477 combination with lenalidomide, CCS1477 combination with lenalidomide and daratumumab

    Drug: CCS1477 · Drug: Pomalidomide · Drug: Dexamethasone · Drug: Bortezomib · Drug: Ixazomib · Drug: Elranatamab · Drug: Teclistamab · Drug: Lenalidomide · Drug: Daratumumab

  • Experimental
    CCS1477 monotherapy expansion and combination dose finding and expansion - AML

    CCS1477 monotherapy, CCS1477 combination with azacitidine, CCS1477 combination with azacitidine and venetoclax

    Drug: CCS1477 · Drug: Azacitidine · Drug: Venetoclax

  • Experimental
    CCS1477 monotherapy expansion and combination dose finding and expansion - Higher risk MDS

    CCS1477 monotherapy, CCS1477 combination with azacitidine

    Drug: CCS1477 · Drug: Azacitidine

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence of treatment-related adverse events

    Treatment-related adverse events and serious adverse events

    Time frame: Up to 12 months

  2. Incidence of laboratory abnormalities

    Laboratory abnormalities characterised by type, frequency, severity and timing

    Time frame: Up to 12 months

Secondary outcomes

  1. Response rate

    Defined as number of patients who have a response according to * RECIL criteria (NHL) * IMWG criteria (Multiple myeloma) * ELN recommendations 2017 (AML)

    Time frame: Up to 12 months

  2. Duration of Response

    Defined as the time from start of treatment until disease progression

    Time frame: Up to 12 months

  3. AUC of CCS1477

    Area under the plasma concentration-time curve (AUC) from time 0 to the time of the last measurable concentration of CCS1477

    Time frame: 35 days

  4. Cmax of CCS1477

    Maximum observed plasma concentration (Cmax) of CCS1477

    Time frame: 35 days

07

Study locations

34 of 39 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — At this stage, is not currently planned that any IPD information will be shared with other researchers outside of the Sponsor and Clinical Research Organisations involved in the conduct of this study.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2019 (actual). Primary completion is estimated for Mar 2027, 91 months after the start.

Of 64 phase 1/2 interventional studies under Hematologic Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 51 and three quarters within 127. This study's planned 91 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 12, 2019
First posted
Aug 28, 2019
StartActual
Aug 9, 2019
Primary completionEst.
Mar 31, 2027
CompletionEst.
Mar 31, 2027
Last update
Jun 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04068597
Lead sponsor
CellCentric Ltd.
Responsible party
Sponsor
First posted
Aug 28, 2019
Start date
Aug 9, 2019
Primary completion
Mar 31, 2027 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Jun 24, 2026

Study contacts

Tomasz Knurowski, PhD
Contact
Tomasz.Knurowski@cellcentric.com
07882871299
Karen Clegg, MD, MFPM
Contact
Karen.Clegg@cellcentric.com
Tim Somervaille
principal investigator · The Christie NHS Foundation Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CCS1477

Start the discussion